Immutep logo

Immutep Share Price (NASDAQ: IMMP)

$1.71

-0.06

(-3.39%)

Live

Last updated on

Check the interactive Immutep Stock chart to analyse performance

Immutep stock performance

as on August 26, 2025 at 12:39 AM IST

  • Today's Low:$1.70
    Today's High:$1.75

    Day's Volatility :2.86%

  • 52 Weeks Low:$1.32
    52 Weeks High:$2.72

    52 Weeks Volatility :51.47%

Immutep Stock Returns

PeriodImmutep LtdSector (Health Care)Index (Russel 2000)
3 Months
-11.06%
6.0%
0.0%
6 Months
-6.35%
-7.2%
0.0%
1 Year
-25.94%
-11.1%
0.0%
3 Years
-12.38%
5.5%
-10.0%

Immutep Ltd Key Stats

Check Immutep key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.77
Open
$1.64
Today's High
$1.75
Today's Low
$1.7
Market Capitalization
$257.6M
Today's Volume
$136.0K
52 Week High
$2.72
52 Week Low
$1.32
Revenue TTM
$4.9M
EBITDA
$-48.7M
Earnings Per Share (EPS)
$-0.22
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-30.45%

Stock Returns calculator for Immutep Stock including INR - Dollar returns

The Immutep stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Immutep investment value today

Current value as on today

₹75,883

Returns

₹24,117

(-24.12%)

Returns from Immutep Stock

₹28,452 (-28.45%)

Dollar Returns*

₹4,335 (+4.33%)

Indian investors sentiment towards Immutep Stock

-40%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Immutep Stock from India on INDmoney has decreased by -40% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immutep Ltd

  • Name

    Holdings %

  • BlackRock Inc

    0.45%

  • Meridian Wealth Management, LLC

    0.26%

  • XY Capital Ltd

    0.09%

  • Steward Partners Investment Advisory, LLC

    0.04%

  • Jane Street Group LLC

    0.04%

  • Susquehanna International Group, LLP

    0.03%

Analyst Recommendation on Immutep Stock

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Immutep(by analysts ranked 0 to 5 stars)

Immutep Share Price Target

What analysts predicted

Upside of 455.56%

Target:

$9.50

Current:

$1.71

Immutep share price target is $9.50, a slight Upside of 455.56% compared to current price of $1.71 as per analysts' prediction.

Immutep Stock Insights

  • Price Movement

    In the last 3 months, IMMP stock has moved down by -8.8%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.73M → 3.14M (in $), with an average increase of 45.0% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -19.27M → -22.37M (in $), with an average decrease of 3.9% per quarter
  • IMMP vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 93.9%
  • IMMP vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 128.5%
  • Price to Sales

    ForIMMP every $1 of sales, investors are willing to pay $44.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Immutep Ltd Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$2.6M
↑ 9.59%
Net Income
$-28.4M
↑ 7.07%
Net Profit Margin
-1.1K%
↑ 26.17%

Immutep Technicals Summary

Sell

Neutral

Buy

Immutep is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Immutep Ltd Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Immutep Ltd logo
-1.67%
-6.35%
-25.94%
-12.38%
31.11%
Regeneron Pharmaceuticals, Inc. logo
5.52%
-17.35%
-50.85%
-1.12%
-3.68%
Beone Medicines Ltd logo
6.51%
21.35%
57.45%
73.21%
25.84%
Vertex Pharmaceuticals Incorporated logo
-14.26%
-17.97%
-18.13%
40.27%
45.64%
Alnylam Pharmaceuticals, Inc. logo
39.9%
82.53%
68.83%
115.41%
241.51%

About Immutep Ltd

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Organization
Immutep
Employees
0
CEO
Mr. Marc Voigt
Industry
Health Technology

Key Management of Immutep Ltd

NameTitle
Mr. Marc Voigt
CEO, MD, CFO, Chief Business Officer & Executive Director
Ms. Deanne Miller LLB
COO, General Counsel & Joint Company Secretary
Dr. Frederic Triebel M.D., Ph.D.
Chief Scientific Officer & Executive Director
Mr. Christian Mueller BBA, MSc.
Chief Development Officer
Mr. Stephan Winckels M.D., Ph.D.
Acting Chief Medical Officer
Ms. Indira Naidu
Joint Company Secretary

Important FAQs about investing in IMMP Stock from India :

What is Immutep share price today?

Immutep share price today is $1.71 as on . Immutep share today touched a day high of $1.75 and a low of $1.70.

What is the 52 week high and 52 week low for Immutep share?

Immutep share touched a 52 week high of $2.72 and a 52 week low of $1.32. Immutep stock price today i.e. is trending at $1.71, lower by 37.13% versus the 52 week high.

How to invest in Immutep Stock (IMMP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immutep on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immutep Shares that will get you 0.8772 shares as per Immutep share price of $1.71 per share as on August 26, 2025 at 12:39 AM IST.

What is the minimum amount required to buy Immutep Stock (IMMP) from India?

Indian investors can start investing in Immutep (IMMP) shares with as little as ₹87.537 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.37 in Immutep stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Immutep share’s latest price of $1.71 as on August 26, 2025 at 12:39 AM IST, you will get 5.8480 shares of Immutep. Learn more about fractional shares .

What are the returns that Immutep has given to Indian investors in the last 5 years?

Immutep stock has given 31.11% share price returns and 18.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?